Patient Summit USA 2016

eyeforpharma 10 - 11 October 2016, Sonesta Philadelphia, USA.
The 13th annual Patient Summit USA 2016 is where patient-driven partnerships with stakeholders actually happen. This is not just a talking shop - be one of 300+ senior pharma executives, regulatory authorities, providers, payers, advocates and patients who plan to deliver sustainable solutions to the patient community.

Patient Centricity ...so what?

  • Streamline cultural change by setting a universal framework for patient centricity
  • Prove ROI-driven patient initiatives and get internal buy-in
  • Hear directly from patients and caregivers and mend their disconnect with the industry
  • Overcome roadblocks to advocacy and adherence with an enhanced focus on access programs
  • Navigate a complex regulatory environment while still promoting your patient initiatives

Turn profit-patient into patient-profit
Transforming your profit-patient model into a patient-profit system is one of the biggest shake-ups in pharma's history.

Many major brands are already in the process of creating and developing a new patient-centric approach, and introducing measures to reward staff against patient-oriented metrics.

What was once an 'if?' has become a 'when and how?'. But changing an engrained mind-set requires a collaborative effort; the more companies that encourage–and in some cases enforce–patient-centricity, the more widespread the buy-in will be.

'Profit' is still a valid talking point - it hasn't become a dirty word. What has changed is that it is now being seen as a natural by-product of putting patients first.

Now that patients are being almost universally regarded as pivotal to the sustained growth of pharma, the question turns back to: how will an inverted model still provide profit for pharma and key stakeholders?

The conference aims to help pharma stakeholders share views, and examine ways to put patients at the centre of evolving pharma business models, without damaging profits. Putting patients first needs to be attractive on both the humanistic and fiscal levels in order for patient centricity to thrive.

World Pharma News readers can benefit from an exclusive discount code, save €200 using World Pharma News unique code WorldPharma200

For further information, please visit:
http://www.eyeforpharma.com/patientusa/

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...